Drug Development

First Opinion Vanessa Almendro

Democratizing drug development will be a win for all

First Opinion Nathan Vardi

Is the golden age of biotech stocks over?

Biotech Matthew Herper

Novavax replaces CEO, citing need for ‘fresh perspective’

Biotech Adam Feuerstein

Arrowhead RNA treatment improves liver scarring in patients, but so does a placebo, clouding study results

Opinions+ Patricia Hurter

Continuous manufacturing can help pharma companies save time, money, and more

Biotech Jason Mast

Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success

First Opinion Peter J. Pitts

The Aduhelm Operetta: ‘I’ve got a little list’

Health Rick Berke

A letter from the executive editor: The Aduhelm Files

First Opinion Richard Marfuggi, Aparna Ahuja and Rick A. Bright

Lessons learned from the deadly combination of sepsis and Covid-19

Biotech Jason Mast

Drugmakers ask regulators to change standards on new Covid antibody drugs for most vulnerable

Biotech Jason Mast

In bid to beat Bristol Myers, Takeda buys Nimbus’ anti-inflammatory drug for $4 billion

Pharmalot Ed Silverman

Ongoing problems with a new European clinical trial registry could cause ‘catastrophe’

Pharmalot Ed Silverman

Cambodia halts exports of non-human primates, threatening drug discovery efforts

Politics Bob Herman

Medicare chief: ‘Door is really open’ on coverage for new Alzheimer’s drug

Biotech Matthew Herper and Allison DeAngelis

‘This is not a cure’: Consensus begins to emerge on new Alzheimer’s drug

First Opinion Arthur L. Caplan and Kenneth I. Moch

Breakthrough Therapies Act: Good idea, wrong solution

In the Lab Megan Molteni

On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Biotech Jonathan Wosen

Vertex revolutionized cystic fibrosis treatment. Its executives say that’s just the start

Biotech Adam Feuerstein, Jason Mast and Damian Garde

‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming

Health Eleanor Cummins

After decades of setbacks, scientists make strides toward the holy grail of male birth control

Pharmalot Ed Silverman

More drugmakers are expanding access in poorer countries, but progress continues to lag overall

Biotech Jonathan Wosen

After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing

Health Andrew Joseph and Jason Mast

U.S. set to face third Covid winter, this time without key tools and treatments

Health Jason Mast

drug development

Most Read

The Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?

After years of lax oversight, the NIH is starting to contact institutions about unreported clinical trial results

A ‘blank check’: Bill to boost antibiotic development blasted as a ‘flawed’ giveaway to pharma

A leaked version of a U.K.-India free trade deal sparks alarm over access to medicines

Here’s why we’re not prepared for the next wave of biotech innovation

Novel solution to biotech’s market valuation woes: Just give the cash back

Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups

Alphabet’s AI predicted the structure of 200 million proteins. Can it really speed up drug discovery?

All Coverage

Democratizing drug development will be a win for all

Is the golden age of biotech stocks over?

Novavax replaces CEO, citing need for ‘fresh perspective’

Arrowhead RNA treatment improves liver scarring in patients, but so does a placebo, clouding study results

Continuous manufacturing can help pharma companies save time, money, and more

Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success

The Aduhelm Operetta: ‘I’ve got a little list’

A letter from the executive editor: The Aduhelm Files

Lessons learned from the deadly combination of sepsis and Covid-19

Drugmakers ask regulators to change standards on new Covid antibody drugs for most vulnerable

In bid to beat Bristol Myers, Takeda buys Nimbus’ anti-inflammatory drug for $4 billion

Ongoing problems with a new European clinical trial registry could cause ‘catastrophe’

Cambodia halts exports of non-human primates, threatening drug discovery efforts

Medicare chief: ‘Door is really open’ on coverage for new Alzheimer’s drug

‘This is not a cure’: Consensus begins to emerge on new Alzheimer’s drug

Breakthrough Therapies Act: Good idea, wrong solution

On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues

Up and down the ladder: The latest comings and goings

Vertex revolutionized cystic fibrosis treatment. Its executives say that’s just the start

‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming

After decades of setbacks, scientists make strides toward the holy grail of male birth control

More drugmakers are expanding access in poorer countries, but progress continues to lag overall

After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing

U.S. set to face third Covid winter, this time without key tools and treatments

FDA panel votes against Veru’s drug for severe Covid

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day